RxDoctor Payments Data

Manuel Gurule, MD

Neurology · Albuquerque, NMNPI 1235297839

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 691 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 47 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,164 and has fallen 60.7% since, to $851 in 2025.

$9,156in general payments, 2019–2025

Across 691 payments — averaging $13.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Teva Pharmaceuticals USA, Inc.$787
  • Sunovion Pharmaceuticals Inc.$593
  • Lilly USA, LLC$563
  • UCB, Inc.$562
  • Amgen$537
  • plus $4K from 41 others

What the payments were for

  • Food & beverage$9,155100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,156 in reported general payments places this provider in the 85th percentile of 91 neurology providers in New Mexico.

See all neurology providers in New Mexico

Medicare billing

Part B allowed, 2024
$75,741
Medicare patients
201
Services billed
489

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aimovig AutoinjectorErenumab-Aooe112$96,700
UbrelvyUbrogepant55$66,407
Emgality PenGalcanezumab-Gnlm86$64,127
Nurtec OdtRimegepant Sulfate20$44,977
BriviactBrivaracetam14$19,372
QuliptaAtogepant18$19,300
Carbamazepine ErCarbamazepine71$11,328
Memantine Hcl205$8,638
Levetiracetam233$8,572
Carbidopa-LevodopaCarbidopa/Levodopa158$6,053
Gabapentin163$4,043
Carbamazepine51$3,851
Levetiracetam ErLevetiracetam21$2,942
Donepezil Hcl155$2,496
Topiramate98$2,222

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$1,930$85,70773 claims
PfizerNurtec Odt$107$44,97720 claims
UCB, Inc.Briviact$562$19,37214 claims
Upsher-smith Laboratories LLCTopiramate$162$2,22298 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 91 neurology providers in New Mexico.

Other neurology in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →